Background Clinical and animal studies have reported conflicting results regarding the effect
of ketamine on cognitive function, although increasing evidence supports a rapid and …

Introduction Ketamine treatment prompts a rapid antidepressant response in treatment-
resistant depression (TRD). We performed an exploratory investigation of how ketamine …

Background Ketamine demonstrated rapid antidepressant effects in treatment-resistant
depression (TRD). However, evaluation of ketamine's neurocognitive effect in TRD is …

Background Recent studies have suggested that neurocognition is changed after repeated
infusions of ketamine in patients with treatment-resistant depression (TRD). The objective of …

Background Ketamine has emerged as a rapid-acting antidepressant in treatment-resistant
depression (TRD) increasingly used in non-research, clinical settings. Few studies …

The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid
antidepressant effects in treatment-resistant depression (TRD). However, evaluation of …

Background A single low-dose ketamine infusion exhibited a rapid antidepressant effect
within 1 h. Despite its short biological half-life (approximately 3 h), the antidepressant effect …

Replicated evidence has documented cognitive deficits in populations with treatment-
resistant depression (TRD). Approximately 40% of patients with MDD present with …

Background Ketamine has been showing high efficacy and rapid antidepressant effect.
However, studies of ketamine infusion wash subjects out from prior antidepressants, which …

Background: Ketamine has proven to have rapid, robust antidepressant effects on treatment-
resistant depression. However, whether repeated ketamine infusions would cause short-and …